Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug